Literature DB >> 25466530

Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease.

M R Allen1, C L Newman, N Chen, M Granke, J S Nyman, S M Moe.   

Abstract

UNLABELLED: Chronic kidney disease (CKD) increases fracture risk. The results of this work point to changes in bone collagen and bone hydration as playing a role in bone fragility associated with CKD.
INTRODUCTION: Clinical data have documented a clear increase in fracture risk associated with chronic kidney disease (CKD). Preclinical studies have shown reductions in bone mechanical properties although the tissue-level mechanisms for these differences remain unclear. The goal of this study was to assess collagen cross-links and matrix hydration, two variables known to affect mechanical properties, in animals with either high- or low-turnover CKD.
METHODS: At 35 weeks of age (>75% reduction in kidney function), the femoral diaphysis of male Cy/+ rats with high or low bone turnover rates, along with normal littermate (NL) controls, were assessed for collagen cross-links (pyridinoline (Pyd), deoxypyridinoline (Dpd), and pentosidine (PE)) using a high-performance liquid chromatography (HPLC) assay as well as pore and bound water per volume (pw and bw) using a (1)H nuclear magnetic resonance (NMR) technique. Material-level biomechanical properties were calculated based on previously published whole bone mechanical tests.
RESULTS: Cortical bone from animals with high-turnover disease had lower Pyd and Dpd cross-link levels (-21% each), lower bw (-10%), higher PE (+71%), and higher pw (+46%) compared to NL. Animals with low turnover had higher Dpd, PE (+71%), and bw (+7%) along with lower pw (-60%) compared to NL. Both high- and low-turnover animals had reduced material-level bone toughness compared to NL animals as determined by three-point bending.
CONCLUSIONS: These data document an increase in skeletal PE with advanced CKD that is independent of bone turnover rate and inversely related to decline in kidney function. Although hydration changes occur in both high- and low-turnover disease, the data suggest that nonenzymatic collagen cross-links may be a key factor in compromised mechanical properties of CKD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25466530      PMCID: PMC4512757          DOI: 10.1007/s00198-014-2978-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  49 in total

1.  Influence of nonenzymatic glycation on biomechanical properties of cortical bone.

Authors:  D Vashishth; G J Gibson; J I Khoury; M B Schaffler; J Kimura; D P Fyhrie
Journal:  Bone       Date:  2001-02       Impact factor: 4.398

2.  The role of collagen in determining bone mechanical properties.

Authors:  X Wang; R A Bank; J M TeKoppele; C M Agrawal
Journal:  J Orthop Res       Date:  2001-11       Impact factor: 3.494

3.  Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties.

Authors:  Maxime A Gallant; Drew M Brown; Max Hammond; Joseph M Wallace; Jiang Du; Alix C Deymier-Black; Jonathan D Almer; Stuart R Stock; Matthew R Allen; David B Burr
Journal:  Bone       Date:  2014-01-24       Impact factor: 4.398

4.  Validation of quantitative bound- and pore-water imaging in cortical bone.

Authors:  Mary Kate Manhard; R Adam Horch; Kevin D Harkins; Daniel F Gochberg; Jeffry S Nyman; Mark D Does
Journal:  Magn Reson Med       Date:  2013-07-22       Impact factor: 4.668

5.  Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.

Authors:  Mohammed E Suliman; Olof Heimbürger; Peter Bárány; Björn Anderstam; Roberto Pecoits-Filho; Ernesto Rodríguez Ayala; A Rashid Qureshi; Ingela Fehrman-Ekholm; Bengt Lindholm; Peter Stenvinkel
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

Review 6.  Evaluating bone quality in patients with chronic kidney disease.

Authors:  Hartmut H Malluche; Daniel S Porter; David Pienkowski
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

Review 7.  Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?

Authors:  Sandeep K Mallipattu; Jaime Uribarri
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

8.  A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.

Authors:  Sharon M Moe; Neal X Chen; Christopher L Newman; Vincent H Gattone; Jason M Organ; Xianming Chen; Matthew R Allen
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

9.  Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy.

Authors:  Chiharu Aoki; Kenta Uto; Kazuho Honda; Yoshiharu Kato; Hideaki Oda
Journal:  Lab Invest       Date:  2013-08-26       Impact factor: 5.662

10.  Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease.

Authors:  Christopher L Newman; Sharon M Moe; Neal X Chen; Max A Hammond; Joseph M Wallace; Jeffry S Nyman; Matthew R Allen
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more
  18 in total

1.  Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

Authors:  Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

2.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

3.  Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions.

Authors:  Christopher L Newman; Neal X Chen; Eric Smith; Mark Smith; Drew Brown; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2015-04-17       Impact factor: 4.398

4.  Moderate chronic kidney disease impairs bone quality in C57Bl/6J mice.

Authors:  Chelsea M Heveran; Alicia M Ortega; Andrew Cureton; Ryan Clark; Eric W Livingston; Ted A Bateman; Moshe Levi; Karen B King; Virginia L Ferguson
Journal:  Bone       Date:  2016-02-06       Impact factor: 4.398

Review 5.  Poor bone matrix quality: What can be done about it?

Authors:  Asier Muñoz; Anxhela Docaj; Maialen Ugarteburu; Alessandra Carriero
Journal:  Curr Osteoporos Rep       Date:  2021-08-20       Impact factor: 5.096

6.  Time course of rapid bone loss and cortical porosity formation observed by longitudinal μCT in a rat model of CKD.

Authors:  Erin M B McNerny; Dorothy T Buening; Mohammad W Aref; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-05-03       Impact factor: 4.398

7.  Chronic kidney disease and aging differentially diminish bone material and microarchitecture in C57Bl/6 mice.

Authors:  Chelsea M Heveran; Charles A Schurman; Claire Acevedo; Eric W Livingston; Danielle Howe; Eric G Schaible; Heather B Hunt; Adam Rauff; Eve Donnelly; R Dana Carpenter; Moshe Levi; Anthony G Lau; Ted A Bateman; Tamara Alliston; Karen B King; Virginia L Ferguson
Journal:  Bone       Date:  2019-05-02       Impact factor: 4.398

8.  Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.

Authors:  Christopher L Newman; Nannan Tian; Max A Hammond; Joseph M Wallace; Drew M Brown; Neal X Chen; Sharon M Moe; Matthew R Allen
Journal:  Am J Nephrol       Date:  2016-02-17       Impact factor: 3.754

9.  Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive kidney disease.

Authors:  Jason M Organ; Andrew Srisuwananukorn; Paige Price; Jeffery E Joll; Kelly C Biro; Joseph E Rupert; Neal X Chen; Keith G Avin; Sharon M Moe; Matthew R Allen
Journal:  Nephrol Dial Transplant       Date:  2015-10-05       Impact factor: 5.992

Review 10.  What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease.

Authors:  Matthew R Allen; Mohammad W Aref
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.